Monte Rosa Therapeutics
GLUE
69 hedge funds and large institutions have $310M invested in Monte Rosa Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 7 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
3% more funds holding
Funds holding: 67 → 69 (+2)
1% less capital invested
Capital invested by funds: $314M → $310M (-$4.65M)
4.81% less ownership
Funds ownership: 85.38% → 80.57% (-4.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$2.61M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$1.82M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.42M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$217K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$9.24M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$3.89M |
| 3 |
Millennium Management
New York
|
-$1.92M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$1.51M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.42M |
GLUE Hedge Fund Activity: Q1 2023 in Review
69 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2023, worth a combined $310M — down 1.5% from $314M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GLUE positions and 7 closed out — a net gain of 2 holders — while 23 added to existing stakes and 20 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $2.61M. The largest seller was RTW Investments, exiting entirely with an estimated $9.24M sold.
- 69 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2023, up from 67 in Q4 2022.
- Funds reported $310M of Monte Rosa Therapeutics stock for Q1 2023, down 1.5% quarter-over-quarter.
- 9 funds opened new Monte Rosa Therapeutics positions in Q1 2023 and 7 closed out, a net change of +2 holders.
- The largest Monte Rosa Therapeutics buyer in Q1 2023 was Baker Bros. Advisors, an estimated $2.61M added.
- The largest Monte Rosa Therapeutics seller in Q1 2023 was RTW Investments, an estimated $9.24M sold.
Based on aggregated 13F filings for Q1 2023.